Previous 10 | Next 10 |
Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...
As a statistician and math enthusiast, it was torture reviewing released Northwest Bio’s ( OTCQB:NWBO ) blinded data, and updated statistics showcasing the blinded results of the DCVax-L Phase III trial from back in June 2018. Reading the positive outlook of the trial through the ey...
Insider buying decreased significantly last week with insiders purchasing $11.65 million of stock compared to $48.31 million in the week prior. Selling also decreased with insiders selling $569.34 million of stock last week compared to $714.05 million in the week prior. Sell/Buy Ratio: The...
I Don’t Feel Comfortable in Info and Data Tech at These Levels My go-to “fast-Money trades” are the chips, software and Internet-enabled business stocks. I understand the underlying economics, and that gives me the comfort to be aggressive when conditions call for it...
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
Let’s Just Say That I’m Early Right now, there are just no negatives ahead of us. Earnings so far are surprising to the upside, starting with the big financial names. This opens a window into the health of the economy from a macro perspective. The big banks are doing really...
Shares of NovoCure (NASDAQ: NVCR) , a medical device company focused on treating tumors , were up about 10% as of 3:20 p.m. EST on Thursday. There doesn't appear to be any company-specific news that can justify the move today. But NovoCure shared some bullish news with investors earlier in t...
The following slide deck was published by NovoCure Limited in conjunction with this Read more ...
I t’s So Easy to Stay Long and Trade, Right? How Can you Lighten Your Risk? You Can and You Should In my Sunday note, I was very cautious on high beta names. Of course, Tesla ( TSLA ) was my example and it promptly ran up 50 points yesterday on no new news. Stocks always seem to ma...
January 13, 2020 Palm Beach, FL – January 13, 2020 – The global pain management devices market size is expected to reach USD 9.3 billion by 2026 registering a CAGR of 7.6%, according to a new study by Grand View Research, Inc. The global prevalence of diabetes i...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...